Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03738865
Other study ID # XSGP-304
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 27, 2018
Est. completion date April 2, 2019

Study information

Verified date May 2020
Source Xeris Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus. The study involves two daytime clinical research center (CRC) visits with random assignment to receive G-Pen glucagon 1 mg during one period and Novo Glucagon 1 mg during the other. Each daytime visit is preceded by an overnight stay in the CRC. In the morning of the inpatient study visit, the subject is brought into a state of severe hypoglycemia through IV administration of regular insulin diluted in normal saline. After a hypoglycemic state with plasma glucose < 54 mg/dL (3 mmol/L) is verified, the subject is administered a dose of G-Pen or Novo Glucagon via subcutaneous injection. Plasma glucose levels are monitored for up to 180 minutes post-dosing, with a value of >70.0 mg/dL (3.89 mmol/L) or an increase of > 20 mg/dL (>1.11 mmol/L) within 30 minutes of glucagon administration indicating a positive response. After 3 hours, the subject is given a meal and discharged when medically stable. After a wash-out period of 7 to 28 days, subjects return to the CRC, and the procedures are repeated with each subject crossed over to the other treatment. A follow-up visit as a safety check is conducted 2-7 days following administration of the final dose of study drug.


Recruitment information / eligibility

Status Completed
Enrollment 132
Est. completion date April 2, 2019
Est. primary completion date March 29, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Males and non-pregnant females diagnosed with type 1 diabetes (T1D) for at least 24 months.

2. Current usage of daily insulin treatment that includes having an assigned "correction factor" for managing hyperglycemia.

3. Age 18 to 75 years, inclusive.

4. Random serum C-peptide concentration < 0.6 ng/mL.

5. Willingness to follow all study procedures, including attending all clinic visits.

6. Subject has provided informed consent as evidenced by a signed and dated informed consent form (ICF) completed before any trial-related activities occur.

Exclusion Criteria:

1. Pregnancy

2. Glycated hemoglobin (HbA1c) > 10% at Screening.

3. Body mass index (BMI) > 40 kg/m2.

4. Renal insufficiency (serum creatinine greater than 3.0 mg/dL) or end-stage renal disease requiring renal replacement therapy.

5. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal to or greater than 3 times the upper limit of normal.

6. Hepatic synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL.

7. Hematocrit < 30%.

8. Blood pressure (BP) readings at Screening where systolic blood pressure (SBP) < 90 or > 150 mm Hg, and diastolic blood pressure (DBP) < 50 or > 100 mm Hg.

9. Clinically significant electrocardiogram (ECG) abnormalities.

10. Use of total insulin dose per day > 2 U/kg.

11. Inadequate venous access.

12. Congestive heart failure, New York Heart Association (NYHA) class III or IV.

13. History of myocardial infarction, unstable angina, or revascularization within the past 6 months.

14. History of a cerebrovascular accident in the past 6 months or with major neurological deficits.

15. Active malignancy within 5 years from Screening, except basal cell or squamous cell skin cancers. Any history of breast cancer or malignant melanoma will be exclusionary.

16. Major surgical operation within 30 days prior to Screening.

17. Current seizure disorder (other than with suspect or documented hypoglycemia).

18. Current bleeding disorder, treatment with warfarin, or platelet count below 50 × 109 per liter.

19. History of pheochromocytoma or disorder with increased risk of pheochromocytoma (multiple endocrine neoplasia type 2 (MEN 2), neurofibromatosis, or Von Hippel-Lindau disease).

20. History of insulinoma.

21. History of allergies to glucagon or glucagon-like products, or any history of significant hypersensitivity to glucagon or any related products or to any of the excipients (DMSO and trehalose) in the investigational formulation.

22. History of glycogen storage disease.

23. Subject tests positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection (hepatitis B surface antigen positive [HBsAg+]) at Screening.

24. Active substance other than tetrahydrocannabinol (THC) or alcohol abuse (more than 21 drinks per week for male subjects or 14 drinks per week for female subject).

25. Administration of glucagon within 7 days of Screening.

26. Participation in other studies involving administration of an investigational drug or device within 30 days or 5 half-lives, whichever is longer, before Screening for the current study and during participation in the current study.

27. Any other reason the Investigator deems exclusionary.

Study Design


Intervention

Drug:
G-Pen
1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
Novo Glucagon
1 mg subcutaneous injection of Novo Glucagon (glucagon injection)

Locations

Country Name City State
Austria Medizinische Universität Graz-Center for Medical Research Graz
Canada AltaSciences Montréal Quebec
Canada LMC Diabetes & Endocrinology Toronto Ontario
United States Atlanta Diabetes Associates Atlanta Georgia
United States PPD-Las Vegas Clinical Research Unit Las Vegas Nevada
United States Rainier Research Center Renton Washington
United States Diablo Clinical Research Walnut Creek California

Sponsors (2)

Lead Sponsor Collaborator
Xeris Pharmaceuticals Empiristat, Inc.

Countries where clinical trial is conducted

United States,  Austria,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Severe Hypoglycemia Rescue Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) or an increase in plasma glucose concentration > 20 mg/dL (> 1.11 mmol/L) within 30 minutes after administration of glucagon At 30 minutes following administration of study drug
Secondary Plasma Glucose Response 1 Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) within 30 minutes of a decision to dose At 30 minutes following a decision to administer study drug
Secondary Plasma Glucose Response 2 Number of subjects with an increase in plasma glucose concentration > 20 mg/dL (> 1.11 mmol/L) after administration of glucagon. At 0-30 minutes following a decision to administer study drug
Secondary Administration Time Mean time (minutes) to administer study drug from a decision to dose At 0-10 minutes from a decision to administer study drug
Secondary Hypoglycemia Resolution Mean time (minutes) to complete resolution of the overall sensation of hypoglycemia from a decision to dose At 0-90 minutes following administration of study drug
See also
  Status Clinical Trial Phase
Completed NCT04476472 - Omnipod Horizon™ Automated Glucose Control System Preschool Cohort N/A
Completed NCT03635437 - Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes Phase 1/Phase 2
Completed NCT04909580 - Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes N/A
Active, not recruiting NCT00679042 - Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Phase 3
Completed NCT03293082 - Preschool CGM Use and Glucose Variability in Type 1 Diabetes N/A
Completed NCT04016662 - Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D) Phase 4
Completed NCT02527265 - Afrezza Safety and Pharmacokinetics Study in Pediatric Patients Phase 2
Completed NCT03240432 - Wireless Innovation for Seniors With Diabetes Mellitus N/A
Completed NCT03168867 - Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms) N/A
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03669770 - Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Recruiting NCT04096794 - Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Completed NCT02882737 - The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus N/A
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Completed NCT02596204 - Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring N/A
Completed NCT02558491 - Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM N/A
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A
Completed NCT02562313 - A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog® Phase 1